Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants
The coronavirus disease-19 (COVID-19) pandemic has been ongoing since December 2019, with more than 6.3 million deaths reported globally as of August 2022. Despite the success of several SARS-CoV-2 vaccines, the rise in variants, some of which are resistant to the effects of vaccination, highlights...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505662/ https://www.ncbi.nlm.nih.gov/pubmed/36146579 http://dx.doi.org/10.3390/vaccines10091502 |
_version_ | 1784796528939892736 |
---|---|
author | Chen, Liqing Qi, Xiaoxiao Liang, Dan Li, Guiqi Peng, Xiaofang Li, Xiaohui Ke, Bixia Zheng, Huanying Liu, Zhongqiu Ke, Changwen Liao, Guochao Liu, Liang Feng, Qian |
author_facet | Chen, Liqing Qi, Xiaoxiao Liang, Dan Li, Guiqi Peng, Xiaofang Li, Xiaohui Ke, Bixia Zheng, Huanying Liu, Zhongqiu Ke, Changwen Liao, Guochao Liu, Liang Feng, Qian |
author_sort | Chen, Liqing |
collection | PubMed |
description | The coronavirus disease-19 (COVID-19) pandemic has been ongoing since December 2019, with more than 6.3 million deaths reported globally as of August 2022. Despite the success of several SARS-CoV-2 vaccines, the rise in variants, some of which are resistant to the effects of vaccination, highlights the need for a so-called pan-coronavirus (universal) vaccine. Here, we performed an immunogenicity comparison of prototype vaccines containing spike protein receptor-binding domain (RBD) residues 319–541, or spike protein regions S1, S2 and S fused to a histidine-tagged or human IgG1 Fc (hFC) fragment with either a longer (six residues) or shorter (three residues) linker. While all recombinant protein vaccines developed were effective in eliciting humoral immunity, the RBD-hFc vaccine was able to generate a potent neutralizing antibody response as well as a cellular immune response. We then compared the effects of recombinant protein length and linker size on immunogenicity in vivo. We found that a longer recombinant RBD protein (residues 319–583; RBD-Plus-hFc) containing a small alanine linker (AAA) was able to trigger long-lasting, high-titer neutralizing antibodies in mice. Finally, we evaluated cross-neutralization of wild-type and mutant RBD-Plus-hFc vaccines against wild-type, Alpha, Beta, Delta and Omicron SARS-CoV-2 variants. Significantly, at the same antigen dose, wild-type RBD-Plus-hFc immune sera induced broadly neutralizing antibodies against wild-type, Alpha, Beta, Delta and Omicron variants. Taken together, our findings provide valuable information for the continued development of recombinant protein-based SARS-CoV-2 vaccines and a basic foundation for booster vaccinations to avoid reinfection with SARS-CoV-2 variants. |
format | Online Article Text |
id | pubmed-9505662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95056622022-09-24 Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants Chen, Liqing Qi, Xiaoxiao Liang, Dan Li, Guiqi Peng, Xiaofang Li, Xiaohui Ke, Bixia Zheng, Huanying Liu, Zhongqiu Ke, Changwen Liao, Guochao Liu, Liang Feng, Qian Vaccines (Basel) Article The coronavirus disease-19 (COVID-19) pandemic has been ongoing since December 2019, with more than 6.3 million deaths reported globally as of August 2022. Despite the success of several SARS-CoV-2 vaccines, the rise in variants, some of which are resistant to the effects of vaccination, highlights the need for a so-called pan-coronavirus (universal) vaccine. Here, we performed an immunogenicity comparison of prototype vaccines containing spike protein receptor-binding domain (RBD) residues 319–541, or spike protein regions S1, S2 and S fused to a histidine-tagged or human IgG1 Fc (hFC) fragment with either a longer (six residues) or shorter (three residues) linker. While all recombinant protein vaccines developed were effective in eliciting humoral immunity, the RBD-hFc vaccine was able to generate a potent neutralizing antibody response as well as a cellular immune response. We then compared the effects of recombinant protein length and linker size on immunogenicity in vivo. We found that a longer recombinant RBD protein (residues 319–583; RBD-Plus-hFc) containing a small alanine linker (AAA) was able to trigger long-lasting, high-titer neutralizing antibodies in mice. Finally, we evaluated cross-neutralization of wild-type and mutant RBD-Plus-hFc vaccines against wild-type, Alpha, Beta, Delta and Omicron SARS-CoV-2 variants. Significantly, at the same antigen dose, wild-type RBD-Plus-hFc immune sera induced broadly neutralizing antibodies against wild-type, Alpha, Beta, Delta and Omicron variants. Taken together, our findings provide valuable information for the continued development of recombinant protein-based SARS-CoV-2 vaccines and a basic foundation for booster vaccinations to avoid reinfection with SARS-CoV-2 variants. MDPI 2022-09-08 /pmc/articles/PMC9505662/ /pubmed/36146579 http://dx.doi.org/10.3390/vaccines10091502 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Liqing Qi, Xiaoxiao Liang, Dan Li, Guiqi Peng, Xiaofang Li, Xiaohui Ke, Bixia Zheng, Huanying Liu, Zhongqiu Ke, Changwen Liao, Guochao Liu, Liang Feng, Qian Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants |
title | Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants |
title_full | Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants |
title_fullStr | Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants |
title_full_unstemmed | Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants |
title_short | Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants |
title_sort | human fc-conjugated receptor binding domain-based recombinant subunit vaccines with short linker induce potent neutralizing antibodies against multiple sars-cov-2 variants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505662/ https://www.ncbi.nlm.nih.gov/pubmed/36146579 http://dx.doi.org/10.3390/vaccines10091502 |
work_keys_str_mv | AT chenliqing humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants AT qixiaoxiao humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants AT liangdan humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants AT liguiqi humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants AT pengxiaofang humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants AT lixiaohui humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants AT kebixia humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants AT zhenghuanying humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants AT liuzhongqiu humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants AT kechangwen humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants AT liaoguochao humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants AT liuliang humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants AT fengqian humanfcconjugatedreceptorbindingdomainbasedrecombinantsubunitvaccineswithshortlinkerinducepotentneutralizingantibodiesagainstmultiplesarscov2variants |